EMEA-000669-PIP01-09-M02
Key facts
Invented name |
Humenza
|
Active substance |
Split influenza virus, inactivated containing antigen equivalent to A/California/7/2009 (H1N1)-like strain (A/California/7/2009 (NYMC X-179A)), adjuvanted
|
Therapeutic area |
Vaccines
|
Decision number |
P/0022/2019
|
PIP number |
EMEA-000669-PIP01-09-M02
|
Pharmaceutical form(s) |
Suspension and emulsion for injection
|
Condition(s) / indication(s) |
Prevention of influenza
|
Route(s) of administration |
Intramuscular use
|
Contact for public enquiries |
Sanofi Pasteur SA
E-mail: Piplan@sanofipasteur.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|
Compliance procedure number |
EMEA-C-000669-PIP01-09-M02
|
Compliance opinion date |
26/04/2019
|
Compliance outcome |
positive
|